Impact of Supporting People with Advanced Parkinson's Disease on Carer's Quality of Life and Burden [Corrigendum]

Modugno N, Antonini A, Tessitore A, et al. The authors apologize for this error. *Neuropsychiatr Dis Treat*. 2020;16:2899–2912.

The authors have advised that there is an error with the PD characteristics in Table 1 on page 2902. The correct table is shown below.

Table 1 Demographic Characteristics of the Patients and Caregivers and PD Clinical Characteristics

	LCIG (n=53)	CSAI (n=19)	CU (n=54)	P value*,**
Patients Demographics				
Age (years); mean $\pm$ SD (range)	70.26 $\pm$ 7.1 (53-84)	66.0 $\pm$ 6.6 (54-77)	69.57 $\pm$ 9.1 (42-88)	
Male; n (%)	25 (47%)	10 (53%)	29 (54%)	
PD Characteristics				
UPDRS-IV Item 39, N (%)				
Not present	6 (11%)	1 (5%)	0	*0.037, **<0.001
1-25%	37 (70%)	8 (42%)	9 (17%)	
26-50%	9 (17%)	8 (42%)	36 (67%)	
51-75%	1 (2%)	2 (11%)	8 (15%)	
76-100%	0	0	1 (2%)	
PD duration (years), mean $\pm$ SD, (range)	16.38 $\pm$ 5.8 (7-33)	13.58 $\pm$ 4.1 (8-21)	12.83 $\pm$ 5.1 (4-35)	*0.085, **0.0003
Duration of motor fluctuations (years), mean $\pm$ SD, (range)	8.36 $\pm$ 4.8 (1-26)	5.47 $\pm$ 3.5 (2-14)	5.22 $\pm$ 4.1 (1-25)	*0.0099, **<0.0001
Caregivers Characteristics				
Age (years); mean $\pm$ SD (range)	59.19 $\pm$ 13.2 (36-84)	60.26 $\pm$ 12.9 (29-78)	55.89 $\pm$ 12.6 (29-85)	
Female; n (%)	30 (56%)	15 (79%)	43 (80%)	
Daily duration of supporting assistance	N=53	N=19	N=52	
Day and night (24 hours)	26 (49%)	12 (63%)	29 (56%)	*0.1783, **0.2013
During daytime	8 (15%)	4 (21%)	9 (17%)	*0.2762, **0.6155
From 3 to 6 hours per day	19 (36%)	3 (16%)	14 (27%)	*0.3075, **0.0003
Caregiver burden				
ZBI score (mean $\pm$ SD)	29.6 $\pm$ 14.42	35.8 $\pm$ 20.15	31.4 $\pm$ 16.0	*0.328, **0.535

Notes: *LCIG vs. CSAI; **LCIG vs. CU; Two-Sample T-test and Wilcoxon Two Sample Test for PD characteristic analysis; Chi Square Test or Fisher Test for daily time spent for the assistance; *LCIG vs. CSAI; **LCIG vs. CU; Bold indicates statistical significance.

Abbreviations: LCIG, levodopa/carbidopa intestinal gel; CSAI, subcutaneous apomorphine infusion; CU, care as usual; SD, standard deviation; N/A, not available; ZBI, Zarit Burden Interview.

Neuropsychiatric Disease and Treatment

Dovepress

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS, and

is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>